Search

Royalty Pharma PLC (Class A)

Open

SectorGezondheidszorg

59.04 0.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

57.99

Max

59.13

Belangrijke statistieken

By Trading Economics

Inkomsten

-61M

295M

Verkoop

8.6M

631M

K/W

Sectorgemiddelde

30.639

62.58

EPS

1.3

Dividendrendement

1.54

Winstmarge

46.733

Werknemers

100

EBITDA

112M

563M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+6.81% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

1.54%

2.19%

Volgende Winsten

5 aug 2026

Volgende dividenddatum

10 sep 2026

Volgende Ex Dividend datum

14 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.2B

33B

Vorige openingsprijs

58.24

Vorige sluitingsprijs

59.04

Nieuwssentiment

By Acuity

50%

50%

144 / 340 Rangschikking in Healthcare

Royalty Pharma PLC (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 jul 2026, 19:11 UTC

News
Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21 jul 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20 jul 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Peer Vergelijking

Prijswijziging

Royalty Pharma PLC (Class A) Prognose

Koersdoel

By TipRanks

6.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.4 USD  6.81%

Hoogste 66 USD

Laagste 58 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Royalty Pharma PLC (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Sentiment

By Acuity

144 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
help-icon Live chat